Get Alert
Please Wait... Processing your request... Please Wait.
You must sign in to sign-up for alerts.

Please confirm that your email address is correct, so you can successfully receive this alert.

Reviews and Overviews   |    
Psychiatric Disorders From Childhood to Adulthood in 22q11.2 Deletion Syndrome: Results From the International Consortium on Brain and Behavior in 22q11.2 Deletion Syndrome
Maude Schneider, M.Sc.; Martin Debbané, Ph.D.; Anne S. Bassett, M.D., F.R.C.P.C.; Eva W.C. Chow, M.D., F.R.C.P.C.; Wai Lun Alan Fung, M.D., Sc.D.; Marianne B.M. van den Bree, Ph.D.; Michael Owen, M.D., Ph.D.; Kieran C. Murphy, M.D., Ph.D.; Maria Niarchou, Ph.D.; Wendy R. Kates, Ph.D.; Kevin M. Antshel, Ph.D.; Wanda Fremont, M.D.; Donna M. McDonald-McGinn, M.S., C.G.C.; Raquel E. Gur, M.D., Ph.D.; Elaine H. Zackai, M.D.; Jacob Vorstman, M.D., Ph.D.; Sasja N. Duijff, Ph.D.; Petra W.J. Klaassen, M.Sc.; Ann Swillen, Ph.D.; Doron Gothelf, M.D.; Tamar Green, M.D.; Abraham Weizman, M.D.; Therese Van Amelsvoort, M.D., Ph.D.; Laurens Evers, M.D.; Erik Boot, M.D., Ph.D.; Vandana Shashi, M.D.; Stephen R. Hooper, Ph.D.; Carrie E. Bearden, Ph.D.; Maria Jalbrzikowski, Ph.D.; Marco Armando, M.D., Ph.D.; Stefano Vicari, M.D.; Declan G. Murphy, M.D.; Opal Ousley, Ph.D.; Linda E. Campbell, Ph.D.; Tony J. Simon, Ph.D.; Stephan Eliez, M.D.; for the International Consortium on Brain and Behavior in 22q11.2 Deletion Syndrome
Am J Psychiatry 2014;171:627-639. doi:10.1176/appi.ajp.2013.13070864
View Author and Article Information

Dr. Ousley is a collaborator in a Biomarin Pharmaceutical study. The other authors report no financial relationships with commercial interests.

Supported by funding from the NIMH International Consortium on Brain and Behavior in 22q11.2 Deletion Syndrome; the Swiss National Fund to Dr. Eliez (grants PP00B_102864 and 32473B_121996); from the National Center of Competence in Research program Synapsy, financed by the Swiss National Science Foundation, to Dr. Eliez (grant 51AU40_125759); from the Canadian Institutes of Health Research to Drs. Bassett and Chow (grants MOP-97800, MOP-89066, and MOP-74631); from the Ontario Mental Health Foundation to Dr. Chow; from support of Dr. Bassett as the Canada Research Chair in Schizophrenia Genetics and Genomic Disorders and as the Dalglish Chair in 22q11.2 Deletion Syndrome; from the Baily Thomas Charitable Trust to Drs. van den Bree and Owen (grant 2315/1); from the Waterloo Foundation to Drs. van den Bree and Owen (grant 912-1234); from the Wellcome Trust Institutional Strategic Support Fund to Drs. van den Bree and Owen; from the Wellcome Trust to Dr. K.C. Murphy and Dr. Owen (grant GR067869MF); from Ireland’s Health Research Board to Dr. K.C. Murphy (grants RP/2004/30 and RP/2008/169); from the Health Foundation to Drs. K.C. Murphy and D.G. Murphy (grant 1206/188); from NIMH to Dr. Kates (grant MH-064824), Dr. Gur (grant MH-087626), Drs. McDonald-McGinn and Zackai (grant MH-087636), Dr. Shashi (grants MH-78015 and MH-091314), and Dr. Bearden (grant RO1 MH-085953); from the National Institute of Child Health and Human Development to Drs. McDonald-McGinn and Zackai (grant HD-070454), Dr. Bearden (P50 HD-055784 [CART pilot project grant]), and Dr. Simon (grant R01 HD-042974); from the Brain and Behavior Research Foundation (formerly NARSAD) to Dr. Vorstman (Young Investigator Award), Dr. Van Amelsvoort (Young Investigator Award), Dr. Armando (Young Investigator Award), and Dr. Ousley; from the State University of New York Hendricks Fund to Dr. Antshel; from the Basil O’Connor Starter Scholar Research Award by the March of Dimes to Dr. Gothelf (grant 5-FY06-590); from the Binational Science Foundation to Dr. Gothelf (grant 2011378); from the Gazit-Globe Award to Dr. Green; from the Dutch Brain Foundation to Dr. Van Amelsvoort; from the Robert W. Woodruff Fund to Dr. Ousley; from the Simons Foundation to Dr. Ousley; from a Hunter Medical Research Institute Post-Doctoral Fellowship to Dr. Campbell; and from an Australian Training Fellowship awarded by the National Health and Medical Research Council of Australia to Dr. Simon (grant 455614).

From the Office Médico-Pédagogique Research Unit, Department of Psychiatry, University of Geneva School of Medicine, Geneva; the Clinical Genetics Research Program and Clinical Genetics Service, Centre for Addiction and Mental Health, Toronto; the Dalglish Family Hearts and Minds Clinic for 22q11.2 Deletion Syndrome, University Health Network, Toronto; the Department of Psychiatry, University of Toronto; the Institute of Psychological Medicine and Clinical Neurosciences, MRC Centre for Neuropsychiatric Genetics and Genomics, Cardiff University, Cardiff, U.K.; the Department of Psychiatry, Royal College of Surgeons in Ireland, Education and Research Centre, Beaumont Hospital, Dublin; the Department of Psychiatry and Behavioral Sciences, State University of New York at Upstate Medical University, Syracuse, N.Y.; the Department of Psychology, Syracuse University, Syracuse, N.Y.; the Division of Human Genetics, Children’s Hospital of Philadelphia; the Departments of Pediatrics and Psychiatry, Perelman School of Medicine, University of Pennsylvania, Philadelphia; the Department of Psychiatry, Brain Center Rudolf Magnus, University Medical Center, Utrecht, the Netherlands; the Department of Pediatric Psychology, Wilhelmina Children’s Hospital, University Medical Center, Utrecht, the Netherlands; the Centre for Human Genetics, University Hospital Gasthuisberg, and the Department of Human Genetics, University of Leuven, Leuven, Belgium; the Behavioral Neurogenetics Center, Edmond and Lily Safra Children's Hospital, Sheba Medical Center, Tel Hashomer, and Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel; the Department of Psychiatry and Behavioral Sciences, Stanford University School of Medicine, Stanford, Calif.; the Geha Mental Health Center and Felsenstein Medical Research Center, Sackler Faculty of Medicine, Petah Tiqwa, Israel; the Department of Psychiatry and Psychology, Maastricht University, Maastricht, the Netherlands; the Koraalgroup, Heel, the Netherlands; Ipse de Bruggen, Centre for People with Intellectual Disability, Zwammerdam, the Netherlands; the Department of Pediatrics, Division of Medical Genetics, Duke University Medical Center, Durham, N.C.; the Department of Psychiatry, University of North Carolina School of Medicine, Chapel Hill, N.C.; the Semel Institute for Neuroscience and Human Behavior and the Department of Psychology, University of California, Los Angeles; the Child Neuropsychiatry Unit, Department of Neuroscience, Bambino Gesù Children’s Hospital, Rome; the Sackler Institute for Translational Neurodevelopment, Institute of Psychiatry, King's College London; the Department of Psychiatry and Behavioral Sciences, Emory University School of Medicine, Atlanta; the School of Psychology, University of Newcastle, Newcastle, Australia; the MIND Institute and Department of Psychiatry, University of California, Davis.

Address correspondence to Ms. Schneider (maude.schneider@unige.ch).

Copyright © 2014 by the American Psychiatric Association

Received July 05, 2013; Revised November 04, 2013; Accepted December 19, 2013.


Objective  Chromosome 22q11.2 deletion syndrome is a neurogenetic disorder associated with high rates of schizophrenia and other psychiatric conditions. The authors report what is to their knowledge the first large-scale collaborative study of rates and sex distributions of psychiatric disorders from childhood to adulthood in 22q11.2 deletion syndrome. The associations among psychopathology, intellect, and functioning were examined in a subgroup of participants.

Method  The 1,402 participants with 22q11.2 deletion syndrome, ages 6–68 years, were assessed for psychiatric disorders with validated diagnostic instruments. Data on intelligence and adaptive functioning were available for 183 participants ages 6 to 24 years.

Results  Attention deficit hyperactivity disorder (ADHD) was the most frequent disorder in children (37.10%) and was overrepresented in males. Anxiety disorders were more prevalent than mood disorders at all ages, but especially in children and adolescents. Anxiety and unipolar mood disorders were overrepresented in females. Psychotic disorders were present in 41% of adults over age 25. Males did not predominate in psychotic or autism spectrum disorders. Hierarchical regressions in the subgroup revealed that daily living skills were predicted by the presence of anxiety disorders. Psychopathology was not associated with communication or socialization skills.

Conclusions  To the authors’ knowledge, this is the largest study of psychiatric morbidity in 22q11.2 deletion syndrome. It validates previous findings that this condition is one of the strongest risk factors for psychosis. Anxiety and developmental disorders were also prevalent. These results highlight the need to monitor and reduce the long-term burden of psychopathology in 22q11.2 deletion syndrome.

Abstract Teaser
Figures in this Article

Your Session has timed out. Please sign back in to continue.
Sign In Your Session has timed out. Please sign back in to continue.
Sign In to Access Full Content
Sign in via Athens (What is this?)
Athens is a service for single sign-on which enables access to all of an institution's subscriptions on- or off-site.
Not a subscriber?

Subscribe Now/Learn More

PsychiatryOnline subscription options offer access to the DSM-5 library, books, journals, CME, and patient resources. This all-in-one virtual library provides psychiatrists and mental health professionals with key resources for diagnosis, treatment, research, and professional development.

Need more help? PsychiatryOnline Customer Service may be reached by emailing PsychiatryOnline@psych.org or by calling 800-368-5777 (in the U.S.) or 703-907-7322 (outside the U.S.).

FIGURE 1. Age Distribution of 1,402 Participants With 22q11.2 Deletion Syndrome Assessed for Psychiatric Disorders

FIGURE 2. Prevalence of Schizophrenia Spectrum Disorders and Distribution of Specific Disorders by Age in Participants With 22q11.2 Deletion Syndromea

a Among the 235 subjects with schizophrenia spectrum disorders, the prevalence of a schizophrenia diagnosis increased significantly over the age groups (χ2=12.54, df=4, p=0.01), whereas the diagnosis of psychotic disorder not otherwise specified decreased (χ2=17.17, df=4, p=0.002).

Anchor for Jump
TABLE 1.Number of Participants in a Study of Psychiatric Disorders at Each Site in the International Consortium on Brain and Behavior in 22q11.2 Deletion Syndrome
Table Footer Note

a CAPA, Child and Adolescent Psychiatric Assessment (30); SCAN, Schedules for Clinical Assessment in Neuropsychiatry (31); SCID, Structured Clinical Interview for DSM-IV Axis I Disorders (32); ADOS, Autism Diagnostic Observation Schedule (33); K-SADS, Schedule for Affective Disorders and Schizophrenia for School-Age Children (34); ADI-R, Autism Diagnostic Interview–Revised (35); DICA, Diagnostic Interview for Children and Adolescents (36); MINI, Mini International Neuropsychiatric Interview (37); Mini PAS-ADD, Mini Psychiatric Assessment Schedules for Adults With Developmental Disabilities (38); CDISC, Computerized Diagnostic Interview Schedule for Children (39).

Anchor for Jump
TABLE 2.Prevalence of DSM-IV-TR Psychiatric Disorders in Five Age Groups of Subjects With 22q11.2 Deletion Syndrome
Table Footer Note

a Significant increase with age (χ2=214.70, df=4, p<0.001).

Table Footer Note

b Significant decrease with age (χ2=15.49, df=4, p=0.004).

Table Footer Note

c Significant decrease with age (χ2=13.67, df=4, p=0.008).

Table Footer Note

d Significant decrease with age (χ2=57.13, df=4, p<0.001).

Table Footer Note

e Significant decrease with age (χ2=24.57, df=4, p<0.001).

Table Footer Note

f Significant increase with age (χ2=47.35, df=4, p<0.001).

Table Footer Note

g Significant increase with age (χ2=37.88, df=4, p<0.001).

Table Footer Note

h Significant difference across age groups (χ2=14.66, df=4, p=0.05).

Table Footer Note

i Significant difference between children and adolescents (χ2=13.19, df=1, p<0.001) and between adolescents and adults (χ2=4.59, df=1, p=0.04).

Table Footer Note

j Significant difference across age groups (χ2=10.07, df=2, p=0.007).

Table Footer Note

k Nonsignificant difference across age groups (χ2=5.06, df=2, p=0.08).

Anchor for Jump
TABLE 3.Effects of Age, Intellectual Functioning, and Psychiatric Diagnoses on Functional Domains in 183 Individuals Ages 6–24 With 22q11.2 Deletion Syndrome
Table Footer Note

a Significant effect.

Table Footer Note

b Nearly significant effect.



Bassett  AS;  McDonald-McGinn  DM;  Devriendt  K;  Digilio  MC;  Goldenberg  P;  Habel  A;  Marino  B;  Oskarsdottir  S;  Philip  N;  Sullivan  K;  Swillen  A;  Vorstman  J; International 22q11.2 Deletion Syndrome Consortium:  Practical guidelines for managing patients with 22q11.2 deletion syndrome.  J Pediatr 2011; 159: 332–339.e1
Duijff  SN;  Klaassen  PWJ;  de Veye  HFNS;  Beemer  FA;  Sinnema  G;  Vorstman  JAS:  Cognitive development in children with 22q11.2 deletion syndrome.  Br J Psychiatry 2012; 200:462–468
Swillen  A;  Vandeputte  L;  Cracco  J;  Maes  B;  Ghesquière  P;  Devriendt  K;  Fryns  JP:  Neuropsychological, learning and psychosocial profile of primary school aged children with the velo-cardio-facial syndrome (22q11 deletion): evidence for a nonverbal learning disability? Child Neuropsychol 1999; 5:230–241
De Smedt  B;  Devriendt  K;  Fryns  JP;  Vogels  A;  Gewillig  M;  Swillen  A:  Intellectual abilities in a large sample of children with velo-cardio-facial syndrome: an update.  J Intellect Disabil Res 2007; 51:666–670
Evers  LJ;  De Die-Smulders  CE;  Smeets  EE;  Clerkx  MG;  Curfs  LM:  The velo-cardio-facial syndrome: the spectrum of psychiatric problems and cognitive deterioration at adult age.  Genet Couns 2009; 20:307–315
Fung  WLA;  McEvilly  R;  Fong  J;  Silversides  C;  Chow  E;  Bassett  A:  Elevated prevalence of generalized anxiety disorder in adults with 22q11.2 deletion syndrome (letter).  Am J Psychiatry 2010; 167:998
Gothelf  D;  Frisch  A;  Munitz  H;  Rockah  R;  Laufer  N;  Mozes  T;  Hermesh  H;  Weizman  A;  Frydman  M:  Clinical characteristics of schizophrenia associated with velo-cardio-facial syndrome.  Schizophr Res 1999; 35:105–112
Green  T;  Gothelf  D;  Glaser  B;  Debbane  M;  Frisch  A;  Kotler  M;  Weizman  A;  Eliez  S:  Psychiatric disorders and intellectual functioning throughout development in velocardiofacial (22q11.2 deletion) syndrome.  J Am Acad Child Adolesc Psychiatry 2009; 48:1060–1068
Murphy  KC;  Jones  LA;  Owen  MJ:  High rates of schizophrenia in adults with velo-cardio-facial syndrome.  Arch Gen Psychiatry 1999; 56:940–945
Pulver  AE;  Nestadt  G;  Goldberg  R;  Shprintzen  RJ;  Lamacz  M;  Wolyniec  PS;  Morrow  B;  Karayiorgou  M;  Antonarakis  SE;  Housman  D;  Kucheriapati  R:  Psychotic illness in patients diagnosed with velo-cardio-facial syndrome and their relatives.  J Nerv Ment Dis 1994; 182:476–478
Shprintzen  RJ;  Goldberg  R;  Golding-Kushner  KJ;  Marion  RW:  Late-onset psychosis in the velo-cardio-facial syndrome.  Am J Med Genet 1992; 42:141–142
Tang  SX;  Yi  JJ;  Calkins  ME;  Whinna  DA;  Kohler  CG;  Souders  MC;  McDonald-McGinn  DM;  Zackai  EH;  Emanuel  BS;  Gur  RC;  Gur  RE:  Psychiatric disorders in 22q11.2 deletion syndrome are prevalent but undertreated.  Psychol Med  (Epub ahead of print, Sept 9, 2013)
Antshel  KM;  Aneja  A;  Strunge  L;  Peebles  J;  Fremont  WP;  Stallone  K;  Abdulsabur  N;  Higgins  AM;  Shprintzen  RJ;  Kates  WR:  Autistic spectrum disorders in velo-cardio facial syndrome (22q11.2 deletion).  J Autism Dev Disord 2007; 37:1776–1786
Antshel  KM;  Fremont  W;  Roizen  NJ;  Shprintzen  R;  Higgins  AM;  Dhamoon  A;  Kates  WR:  ADHD, major depressive disorder, and simple phobias are prevalent psychiatric conditions in youth with velocardiofacial syndrome.  J Am Acad Child Adolesc Psychiatry 2006; 45:596–603
Antshel  KM;  Shprintzen  R;  Fremont  W;  Higgins  AM;  Faraone  SV;  Kates  WR:  Cognitive and psychiatric predictors to psychosis in velocardiofacial syndrome: a 3-year follow-up study.  J Am Acad Child Adolesc Psychiatry 2010; 49:333–344
Baker  KD;  Skuse  DH:  Adolescents and young adults with 22q11 deletion syndrome: psychopathology in an at-risk group.  Br J Psychiatry 2005; 186:115–120
Feinstein  C;  Eliez  S;  Blasey  CM;  Reiss  AL:  Psychiatric disorders and behavioral problems in children with velocardiofacial syndrome: usefulness as phenotypic indicators of schizophrenia risk.  Biol Psychiatry 2002; 51:312–318
Gothelf  D;  Feinstein  C;  Thompson  T;  Gu  E;  Penniman  L;  Van Stone  E;  Kwon  H;  Eliez  S;  Reiss  AL:  Risk factors for the emergence of psychotic disorders in adolescents with 22q11.2 deletion syndrome.  Am J Psychiatry 2007; 164:663–669
Jolin  EM;  Weller  RA;  Jessani  NR;  Zackai  EH;  McDonald-McGinn  DM;  Weller  EB:  Affective disorders and other psychiatric diagnoses in children and adolescents with 22q11.2 deletion syndrome.  J Affect Disord 2009; 119:177–180
Lewandowski  KE;  Shashi  V;  Berry  PM;  Kwapil  TR:  Schizophrenic-like neurocognitive deficits in children and adolescents with 22q11 deletion syndrome.  Am J Med Genet B Neuropsychiatr Genet 2007; 144B:27–36
Niklasson  L;  Rasmussen  P;  Oskarsdóttir  S;  Gillberg  C:  Chromosome 22q11 deletion syndrome (CATCH 22): neuropsychiatric and neuropsychological aspects.  Dev Med Child Neurol 2002; 44:44–50
Shashi  V;  Veerapandiyan  A;  Schoch  K;  Kwapil  T;  Keshavan  M;  Ip  E;  Hooper  S:  Social skills and associated psychopathology in children with chromosome 22q11.2 deletion syndrome: implications for interventions.  J Intellect Disabil Res 2012; 56:865–878
Stoddard  J;  Niendam  T;  Hendren  R;  Carter  C;  Simon  TJ:  Attenuated positive symptoms of psychosis in adolescents with chromosome 22q11.2 deletion syndrome.  Schizophr Res 2010; 118:118–121
Vorstman  JAS;  Morcus  MEJ;  Duijff  SN;  Klaassen  PWJ;  Heineman-de Boer  JA;  Beemer  FA;  Swaab  H;  Kahn  RS;  van Engeland  H:  The 22q11.2 deletion in children: high rate of autistic disorders and early onset of psychotic symptoms.  J Am Acad Child Adolesc Psychiatry 2006; 45:1104–1113
Young  AS;  Shashi  V;  Schoch  K;  Kwapil  T;  Hooper  SR:  Discordance in diagnoses and treatment of psychiatric disorders in children and adolescents with 22q11.2 deletion syndrome.  Asian J Psychiatr 2011; 4:119–124
Sobin  C;  Kiley-Brabeck  K;  Monk  SH;  Khuri  J;  Karayiorgou  M:  Sex differences in the behavior of children with the 22q11 deletion syndrome.  Psychiatry Res 2009; 166:24–34
Angkustsiri  K;  Leckliter  I;  Tartaglia  N;  Beaton  EA;  Enriquez  J;  Simon  TJ:  An examination of the relationship of anxiety and intelligence to adaptive functioning in children with chromosome 22q11.2 deletion syndrome.  J Dev Behav Pediatr 2012; 33:713–720
Butcher  NJ;  Chow  EWC;  Costain  G;  Karas  D;  Ho  A;  Bassett  AS:  Functional outcomes of adults with 22q11.2 deletion syndrome.  Genet Med 2012; 14:836–843
Delio  M;  Guo  T;  McDonald-McGinn  DM;  Zackai  E;  Herman  S;  Kaminetzky  M;  Higgins  AM;  Coleman  K;  Chow  C;  Jalbrzikowski  M;  Bearden  CE;  Bailey  A;  Vangkilde  A;  Olsen  L;  Olesen  C;  Skovby  F;  Werge  TM;  Templin  L;  Busa  T;  Philip  N;  Swillen  A;  Vermeesch  JR;  Devriendt  K;  Schneider  M;  Dahoun  S;  Eliez  S;  Schoch  K;  Hooper  SR;  Shashi  V;  Samanich  J;  Marion  R;  van Amelsvoort  T;  Boot  E;  Klaassen  P;  Duijff  SN;  Vorstman  J;  Yuen  T;  Silversides  C;  Chow  E;  Bassett  A;  Frisch  A;  Weizman  A;  Gothelf  D;  Niarchou  M;  van den Bree  M;  Owen  MJ;  Suñer  DH;  Andreo  JR;  Armando  M;  Vicari  S;  Digilio  MC;  Auton  A;  Kates  WR;  Wang  T;  Shprintzen  RJ;  Emanuel  BS;  Morrow  BE:  Enhanced maternal origin of the 22q11.2 deletion in velocardiofacial and DiGeorge syndromes.  Am J Hum Genet 2013; 92:439–447; correction, 92:637
Angold  A;  Prendergast  M;  Cox  A;  Harrington  R;  Simonoff  E;  Rutter  M:  The Child and Adolescent Psychiatric Assessment (CAPA).  Psychol Med 1995; 25:739–753
Wing  JK;  Babor  T;  Brugha  T;  Burke  J;  Cooper  JE;  Giel  R;  Jablenski  A;  Regier  D;  Sartorius  N:  SCAN: Schedules for Clinical Assessment in Neuropsychiatry.  Arch Gen Psychiatry 1990; 47:589–593
First  M;  Gibbon  M;  Spitzer  R;  Williams  J:  Structured Clinical Interview for the DSM-IV Axis I Disorders (SCID-I) .  Washington, DC,  American Psychiatric Association, 1996
Lord  C;  Rutter  M;  Goode  S;  Heemsbergen  J;  Jordan  H;  Mawhood  L;  Schopler  E:  Autism Diagnostic Observation Schedule: a standardized observation of communicative and social behavior.  J Autism Dev Disord 1989; 19:185–212
Kaufman  J;  Birmaher  B;  Brent  D;  Rao  U;  Flynn  C;  Moreci  P;  Williamson  D;  Ryan  N:  Schedule for Affective Disorders and Schizophrenia for School-Age Children—Present and Lifetime Version (K-SADS-PL): initial reliability and validity data.  J Am Acad Child Adolesc Psychiatry 1997; 36:980–988
Lord  C;  Rutter  M;  Le Couteur  A:  Autism Diagnostic Interview–Revised: a revised version of a diagnostic interview for caregivers of individuals with possible pervasive developmental disorders.  J Autism Dev Disord 1994; 24:659–685
Reich  W:  Diagnostic Interview for Children and Adolescents (DICA).  J Am Acad Child Adolesc Psychiatry 2000; 39:59–66
Sheehan  DV;  Lecrubier  Y;  Harnett-Sheehan  K;  Janavs  J;  Weiller  E;  Keskiner  A;  Schinka  J;  Knapp  E;  Sheehan  MF;  Dunbar  GC:  The validity of the Mini International Neuropsychiatric Interview (MINI) according to the SCID-P and its reliability.  Eur Psychiatry 1997; 12:232–241
Prosser  H;  Moss  S;  Costello  H;  Simpson  N;  Patel  P;  Rowe  S:  Reliability and validity of the Mini PAS-ADD for assessing psychiatric disorders in adults with intellectual disability.  J Intellect Disabil Res 1998; 42:264–272
Shaffer  D;  Schwab-Stone  M;  Fisher  P;  Cohen  P;  Piacentini  J;  Davies  M;  Conners  CK;  Regier  D:  The Diagnostic Interview Schedule for Children–Revised Version (DISC-R), I: preparation, field testing, interrater reliability, and acceptability.  J Am Acad Child Adolesc Psychiatry 1993; 32:643–650
Sparrow  SS;  Balla  DA;  Cicchetti  DV:  Vineland Adaptive Behavior Scales .  Circle Pines, Minn,  American Guidance Service, 1984
Kessler  RC;  Adler  L;  Barkley  R;  Biederman  J;  Conners  CK;  Demler  O;  Faraone  SV;  Greenhill  LL;  Howes  MJ;  Secnik  K;  Spencer  T;  Ustun  TB;  Walters  EE;  Zaslavsky  AM:  The prevalence and correlates of adult ADHD in the United States: results from the National Comorbidity Survey Replication.  Am J Psychiatry 2006; 163:716–723
Antshel  KM;  Hendricks  K;  Shprintzen  R;  Fremont  W;  Higgins  AM;  Faraone  SV;  Kates  WR:  The longitudinal course of attention deficit/hyperactivity disorder in velo-cardio-facial syndrome.  J Pediatr 2013; 163:187–193.e1
Green  T;  Weinberger  R;  Diamond  A;  Berant  M;  Hirschfeld  L;  Frisch  A;  Zarchi  O;  Weizman  A;  Gothelf  D:  The effect of methylphenidate on prefrontal cognitive functioning, inattention, and hyperactivity in velocardiofacial syndrome.  J Child Adolesc Psychopharmacol 2011; 21:589–595
Ahuja  A;  Martin  J;  Langley  K;  Thapar  A:  Intellectual disability in children with attention deficit hyperactivity disorder.  J Pediatr 2013; 163:890–895.e1
Grizenko  N;  Paci  M;  Joober  R:  Is the inattentive subtype of ADHD different from the combined/hyperactive subtype? J Atten Disord 2010; 13:649–657
Dekker  MC;  Koot  HM:  DSM-IV disorders in children with borderline to moderate intellectual disability. I: prevalence and impact.  J Am Acad Child Adolesc Psychiatry 2003; 42:915–922
Kessler  RC;  Avenevoli  S;  Costello  EJ;  Georgiades  K;  Green  JG;  Gruber  MJ;  He  JP;  Koretz  D;  McLaughlin  KA;  Petukhova  M;  Sampson  NA;  Zaslavsky  AM;  Merikangas  KR:  Prevalence, persistence, and sociodemographic correlates of DSM-IV disorders in the National Comorbidity Survey Replication Adolescent Supplement.  Arch Gen Psychiatry 2012; 69:372–380
Angkustsiri  K;  Goodlin-Jones  B;  Deprey  L;  Brahmbhatt  K;  Harris  S;  Simon  TJ:  Social impairments in chromosome 22q11.2 deletion syndrome (22q11.2DS): autism spectrum disorder or a different endophenotype? J Autism Dev Disord  (Epub ahead of print, Sept 18, 2013)
Schneider  M;  Van der Linden  M;  Glaser  B;  Rizzi  E;  Dahoun  SP;  Hinard  C;  Bartoloni  L;  Antonarakis  SE;  Debbané  M;  Eliez  S:  Preliminary structure and predictive value of attenuated negative symptoms in 22q11.2 deletion syndrome.  Psychiatry Res 2012; 196:277–284
Yuen  T;  Chow  EW;  Silversides  CK;  Bassett  AS:  Premorbid adjustment and schizophrenia in individuals with 22q11.2 deletion syndrome. Schizophr Res 2013; 151:221–225
Baker  K;  Vorstman  JAS:  Is there a core neuropsychiatric phenotype in 22q11.2 deletion syndrome? Curr Opin Neurol 2012; 25:131–137
Karayiorgou  M;  Simon  TJ;  Gogos  JA:  22q11.2 microdeletions: linking DNA structural variation to brain dysfunction and schizophrenia.  Nat Rev Neurosci 2010; 11:402–416
Papolos  DF;  Faedda  GL;  Veit  S;  Goldberg  R;  Morrow  B;  Kucherlapati  R;  Shprintzen  RJ:  Bipolar spectrum disorders in patients diagnosed with velo-cardio-facial syndrome: does a hemizygous deletion of chromosome 22q11 result in bipolar affective disorder? Am J Psychiatry 1996; 153:1541–1547
Kahn  JP;  Meyers  JR:  Treatment of comorbid panic disorder and schizophrenia: evidence for a panic psychosis.  Psychiatr Ann 2000; 30:29–33
Gothelf  D;  Schneider  M;  Green  T;  Debbané  M;  Frisch  A;  Glaser  B;  Zilkha  H;  Schaer  M;  Weizman  A;  Eliez  S:  Risk factors and the evolution of psychosis in 22q11.2 deletion syndrome: a longitudinal 2-site study.  J Am Acad Child Adolesc Psychiatry 2013; 52:1192–1203.e3
Maughan  B;  Rowe  R;  Messer  J;  Goodman  R;  Meltzer  H:  Conduct disorder and oppositional defiant disorder in a national sample: developmental epidemiology.  J Child Psychol Psychiatry 2004; 45:609–621
Merikangas  KR;  He  JP;  Brody  D;  Fisher  PW;  Bourdon  K;  Koretz  DS:  Prevalence and treatment of mental disorders among US children in the 2001-2004 NHANES.  Pediatrics 2010; 125:75–81
Hayward  C;  Sanborn  K:  Puberty and the emergence of gender differences in psychopathology.  J Adolesc Health 2002; 30(4 suppl):49–58
MacCabe  JH;  Murray  RM:  Intellectual functioning in schizophrenia: a marker of neurodevelopmental damage? J Intellect Disabil Res 2004; 48(part 6):519–523
Amminger  GP;  Schäfer  MR;  Papageorgiou  K;  Klier  C;  Cotton  SM;  Harrigan  SM;  Mackinnon  A;  McGorry  PD;  Berger  GE:  Long-chain omega-3 fatty acids for indicated prevention of psychotic disorders.  Arch Gen Psychiatry 2010; 67:146–154
References Container

CME Activity

There is currently no quiz available for this resource. Please click here to go to the CME page to find another.
Submit a Comments
Please read the other comments before you post yours. Contributors must reveal any conflict of interest.
Comments are moderated and will appear on the site at the discertion of APA editorial staff.

* = Required Field
(if multiple authors, separate names by comma)
Example: John Doe

Web of Science® Times Cited: 1

Related Content
The American Psychiatric Publishing Textbook of Psychopharmacology, 4th Edition > Chapter 52.  >
The American Psychiatric Publishing Textbook of Psychopharmacology, 4th Edition > Chapter 52.  >
Manual of Clinical Psychopharmacology, 7th Edition > Chapter 1.  >
Textbook of Traumatic Brain Injury, 2nd Edition > Chapter 28.  >
Dulcan's Textbook of Child and Adolescent Psychiatry > Chapter 52.  >
Topic Collections
Psychiatric News
APA Guidelines
PubMed Articles